NYSE$ATNM
Actinium Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
ATNM Q1 2024 — $35.0M revenue
March 31, 2024 and December 31, 2023, and the results of operations and cash flows for the three months ended March 31, 2024 and 2023, respectively, have. Actinium Pharmaceuticals Inc reported Q1 2024 results. Net income of $8.7M. Headline numbers extracted from the Form 10-Q press release; narrative is light because this row was processed without an LLM call.
- Revenue: $35.0M.
- Net income: $8.7M.
- Filed on Form 10-Q (accession 0001213900-24-036699).
Headline financials
Revenue & EPS history
Actinium · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+0.8%
Avg return
Earnings day
-2.9%
Avg return
5 days after
+2.0%
Avg return
30 days after
53%
28 / 53 earnings
Positive
+46.5%
Q3 2013
Best reaction
-53.5%
Q2 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -1.4% | -3.8% | -19.8% | |
| Q3 2025 | +14.3% | +1.6% | +25.2% | |
| Q2 2025 | -6.5% | +7.1% | +3.9% | |
| Q1 2025 | +6.0% | +1.8% | -8.4% | |
| Q4 2024 | -0.8% | -4.8% | +32.5% | |
| Q3 2024 | -12.3% | -17.0% | -28.1% | |
| Q2 2024 | -53.5% | -66.8% | -70.8% | |
| Q1 2024 | +12.5% | +18.6% | +29.6% | |
| Q4 2023 | +9.3% | +12.9% | -12.3% | |
| Q3 2023 | -12.2% | -9.6% | -7.0% | |
| Q2 2023 | +1.6% | -3.0% | +5.2% | |
| Q1 2023 | +0.8% | +4.1% | -4.6% | |
| Q4 2022 | -5.2% | -5.0% | -5.1% | |
| Q3 2022 | +3.5% | +0.7% | -7.1% | |
| Q2 2022 | +5.6% | +2.6% | +48.8% | |
| Q1 2022 | +4.2% | +9.4% | -7.8% | |
| Q4 2021 | -2.2% | +1.0% | +35.8% | |
| Q3 2021 | +3.2% | -0.8% | -12.6% | |
| Q2 2021 | +2.1% | -1.9% | -10.5% | |
| Q1 2021 | +6.4% | +6.7% | +21.4% | |
| Q4 2020 | +5.2% | +6.0% | +0.0% | |
| Q3 2020 | -3.0% | -9.4% | -5.6% | |
| Q2 2020 | +9.1% | -2.8% | -14.0% | |
| Q1 2020 | -3.1% | -13.5% | +59.8% | |
| Q4 2019 | +4.8% | +0.0% | +66.7% | |
| Q3 2019 | -0.7% | -0.8% | -18.8% | |
| Q2 2019 | +5.9% | -1.4% | -2.3% | |
| Q1 2019 | -5.8% | -9.1% | -9.1% | |
| Q4 2018 | +1.6% | -3.7% | -5.4% | |
| Q3 2018 | -5.6% | -17.4% | -21.3% | |
| Q2 2018 | +6.5% | +8.8% | +16.7% | |
| Q1 2018 | +2.1% | +5.3% | +20.8% | |
| Q4 2017 | -6.0% | -4.6% | -9.6% | |
| Q3 2017 | -2.0% | -7.8% | +9.6% | |
| Q2 2017 | +0.0% | -7.7% | +0.0% | |
| Q1 2017 | -1.4% | -1.4% | -22.9% | |
| Q4 2016 | +3.0% | +4.5% | +9.7% | |
| Q3 2016 | -8.7% | -10.6% | -2.9% | |
| Q2 2016 | -2.3% | -2.3% | -1.7% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | +2.1% | — | — | |
| Q3 2015 | -3.7% | — | — | |
| Q2 2015 | -0.9% | — | — | |
| Q1 2015 | +6.0% | — | — | |
| Q4 2014 | +13.5% | — | — | |
| Q3 2014 | +4.1% | — | — | |
| Q2 2014 | +0.0% | — | — | |
| Q1 2014 | +8.8% | — | — | |
| Q4 2013 | +2.0% | — | — | |
| Q3 2013 | +46.5% | — | — | |
| Q2 2013 | +0.0% | — | — | |
| Q1 2013 | -1.3% | — | — | |
| Q4 2012 | -15.3% | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2011 | — | — | — | |
| Q3 2011 | — | — | — | |
| Q2 2011 | — | — | — | |
| Q1 2011 | — | — | — | |
| Q4 2010 | — | — | — | |
| Q3 2010 | — | — | — | |
| Q2 2010 | — | — | — | |
| Q1 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro